SEGMENTED INFORMATION (Tables)

9 Months Ended

Sep. 30, 2024

SEGMENTED INFORMATION

Schedule of Segmented Revenue and Net Profit/(Loss)

	MRNA Scientific			Chemrex Corporation			BGLC			Total
	Nine months ended September 30, 2024
REVENUE	$	11,224		$	6,975,567		$	-		$	6,986,791
COST OF REVENUE		(6,723	)		(5,999,781	)		-			(6,006,504	)
GROSS PROFIT		4,501			975,786			-			980,287
OTHER INCOME		98,830			1,298,649			-			1,397,479
OPERATING EXPENSES
General and administrative		(475,762	)		(2,149,306	)		(910,180	)		(3,535,248	)
(LOSS)/PROFIT FROM OPERATIONS		(372,431	)		125,129			(910,810	)		(1,157,482	)
FINANCE COSTS		(8,360	)		(6,848	)		(126	)		(15,334	)
(LOSS)/PROFIT BEFORE TAX		(380,791	)		118,281			(910,306	)		(1,172,816	)
Tax expense		-			(77,207	)		-			(77,207	)
NET (LOSS)/PROFIT	$	(380,791	)	$	41,074		$	(910,306	)	$	(1,250,023	)

	MRNA Scientific			Chemrex Corporation			BGLC			Total
	Nine months ended September 30, 2023
REVENUE	$	28,468		$	7,469,271		$	-		$	7,497,739
COST OF REVENUE		(14,849	)		(6,419,947	)		-			(6,434,796	)
GROSS PROFIT		13,619			1,049,324			-			1,062,943
OTHER INCOME		3,922			507,870			-			511,792
OPERATING EXPENSES
General and administrative		(170,590	)		(2,348,127	)		(1,907,360	)		(4,426,077	)
LOSS FROM OPERATIONS		(153,049	)		(790,933	)		(1,907,360	)		(2,851,342	)
FINANCE COSTS		(2,952	)		(6,794	)		-			(9,746	)
LOSS BEFORE TAX		(156,001	)		(797,727	)		(1,907,360	)		(2,861,088	)
Tax expense		-			(76,418	)		-			(76,418	)
NET LOSS	$	(156,001	)	$	(874,145	)	$	(1,907,360	)	$	(2,937,506	)

	AS OF SEPTEMBER 30, 2024 AND DECEMBER 31, 2023
	Total Assets				Total Liabilities
	2024		2023		2024		2023
BGLC & MRNA Scientific	$	4,027,423		5,002,908	$	469,710	$	176,805
Chemrex Corporation		6,967,632		6,462,614		1,137,172		1,601,002
TOTAL		10,995,055		11,465,522		1,606,882		1,777,807